964
Participants
Start Date
December 31, 2010
Primary Completion Date
March 31, 2013
Study Completion Date
August 31, 2013
Benralizumab 2 mg
EOS+ participants received single benralizumab 2 milligram (mg) injection followed by a single placebo injection subcutaneously.
Benralizumab 20 mg
EOS+ participants received single benralizumab 20 mg injection followed by a single placebo injection subcutaneously.
Benralizumab 100 mg
EOS+ and EOS- participants received two benralizumab 50 mg injections subcutaneously.
Placebo
EOS+ and EOS- participants received two placebo injections subcutaneously.
Research Site, Birmingham
Research Site, Los Angeles
Research Site, Orange
Research Site, San Diego
Research Site, Stockton
Research Site, Colorado Springs
Research Site, Denver
Research Site, Waterbury
Research Site, Kissimmee
Research Site, Tampa
Research Site, Stockbridge
Research Site, Normal
Research Site, Baltimore
Research Site, Rochester
Research Site, St Louis
Research Site, Bellevue
Research Site, Summit
Research Site, Rochester
Research Site, Winston-Salem
Research Site, Cincinnati
Research Site, Oklahoma City
Research Site, Blue Bell
Research Site, Pittsburgh
Research Site, Warwick
Research Site, Boerne
Research Site, San Antonio
Research Site, Seattle
Research Site, Caba
Research Site, Ciudad de Buenos Aires
Research Site, San Miguel de Tucumán
Research Site, Santa Fe
Research Site, Curitiba
Research Site, Florianópolis
Research Site, Juiz de Fora
Research Site, Porto Alegre
Research Site, Rio de Janeiro
Research Site, Salvador
Research Site, Santo André
Research Site, São Paulo
Research Site, Pleven
Research Site, Rousse
Research Site, Sofia
Research Site, Troyan Municipality
Research Site, Brampton
Research Site, Toronto
Research Site, La Malbaie
Research Site, Québec
Research Site, Bogotá
Research Site, Guadalajara
Research Site, México
Research Site, Monterrey
Research Site, Morelia
Research Site, Villahermosa
Research Site, Zapopan
Research Site, Lima
Research Site, San Borja
Research Site, San Isidro
Research Site, Surco
Research Site, Bialystok
Research Site, Bydgoszcz
Research Site, Lodz
Research Site, Lublin
Research Site, Ostrów Wielkopolski
Research Site, Piła
Research Site, Poznan
Research Site, Tarnów
Research Site, Warsaw
Research Site, Barnaul
Research Site, Chelyabinsk
Research Site, Kazan'
Research Site, Moscow
Research Site, Novosibirsk
Research Site, Saint Petersburg
Research Site, Yekaterinburg
Lead Sponsor
Collaborators (1)
MedImmune Ltd
INDUSTRY
MedImmune LLC
INDUSTRY